Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Immuron Limited ( (AU:IMC) ).
Immuron reported unaudited global third-quarter sales of AUD$1.5 million, a 16% rise on the prior comparative period, with year-to-date sales to March 2026 up 7% to AUD$5.7 million. Growth was driven by strong performance of Travelan in Australia, modest gains in the U.S., and a sharp quarter-on-quarter rebound in Canada following earlier pipeline fills and new retail listings.
Australian Q3 sales climbed 15% to AUD$0.9 million, underpinned by digital marketing, expanded pharmacy ranging, and increased Southeast Asian travel. U.S. sales rose 1% in Q3 amid enhanced online and social media marketing, while Canadian Q3 sales more than doubled year on year and jumped 82% sequentially, signaling growing brand traction despite lower year-to-date revenue in that market.
More about Immuron Limited
Immuron Limited is an Australian-based, globally integrated biopharmaceutical company focused on gastrointestinal health. Its primary product, Travelan, is an over-the-counter immune supplement designed to target pathogenic bacteria and the toxins they produce in the gastrointestinal tract, catering to travelers and consumers seeking protection against digestive upsets.
Average Trading Volume: 273,592
Technical Sentiment Signal: Sell
Current Market Cap: A$9.15M
Find detailed analytics on IMC stock on TipRanks’ Stock Analysis page.